Leukemia Clinical Trials in Detroit

Showing 1401-1420 of 1,440 trials

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

NCT00491699

The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Non-Small-Cell Lung Cancer

Symphony Evolution, Inc.2 participantsStarted Aug 2007

Los Angeles, California, United States • Atlanta, Georgia, United States • Detroit, Michigan, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

NCT00086099

The primary objectives of this study are: 1. To evaluate whether the addition of amifostine will allow for the safe administration of idarubicin at a dose of 21 mg/m² in combination with standard-dose ara-C in older patients with newly diagnosed, previously untreated acute myeloid leukemia (AML); and 2. To estimate the complete remission rate of induction therapy with amifostine, idarubicin (21 mg/m²), plus ara-C or induction therapy with idarubicin (12 mg/m²) plus ara-C in this patient population.

LeukemiaAcute Myeloid Leukemia

MedImmune LLC54 participantsStarted Jul 2004

San Diego, California, United States • Chicago, Illinois, United States • New Albany, Indiana, United States +16 more locations

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Leukemia Trials in Other Cities

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

CPG 7909 Injection in Non-Small Cell Lung Cancer

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Other Conditions in Detroit